Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
NextCure Analyst Ratings and Price Targets | NASDAQ:NXTC | Benzinga
NextCure Inc has a consensus price target of $7 based on the ratings of 5 analysts. The high is $15 issued by Truist Securities on August 23, 2022. The low is $3 issued by HC Wainwright & Co. on March 17, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 17, 2025, March 7, 2025, and November 11, 2024, respectively. With an average price target of $3.33 between HC Wainwright & Co., there's an implied 486.44% upside for NextCure Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Needham
Piper Sandler
Truist Securities
1calculated from analyst ratings
Analyst Ratings for NextCure
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/17/2025 | Buy Now | 427.8% | HC Wainwright & Co. | Emily Bodnar39% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2025 | Buy Now | 427.8% | HC Wainwright & Co. | Emily Bodnar39% | $4 → $3 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 603.73% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $4 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 603.73% | Needham | Gil Blum51% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 1307.46% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 1307.46% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 1307.46% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 603.73% | Needham | Gil Blum51% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 1307.46% | HC Wainwright & Co. | Emily Bodnar39% | $5 → $8 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 603.73% | Needham | Gil Blum51% | $4 → $4 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 603.73% | Needham | Gil Blum51% | $6 → $4 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 1131.53% | HC Wainwright & Co. | Emily Bodnar39% | → $7 | Initiates | → Buy | Get Alert |
| 08/04/2023 | Buy Now | 955.59% | Needham | Gil Blum51% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 955.59% | Needham | Gil Blum51% | → $6 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 955.59% | Needham | Gil Blum51% | → $6 | Reiterates | → Buy | Get Alert |
| 11/04/2022 | Buy Now | — | Ladenburg Thalmann | Aydin Huseynov35% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/04/2022 | Buy Now | 955.59% | Needham | Gil Blum51% | $12 → $6 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 955.59% | Piper Sandler | Edward Tenthoff52% | $13 → $6 | Maintains | Overweight | Get Alert |
| 08/23/2022 | Buy Now | 2538.99% | Truist Securities | Asthika Goonewardene41% | $19 → $15 | Maintains | Buy | Get Alert |
| 05/23/2022 | Buy Now | 2187.12% | Piper Sandler | Edward Tenthoff52% | $21 → $13 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for NextCure (NXTC) stock?
The latest price target for NextCure (NASDAQ:NXTC) was reported by HC Wainwright & Co. on March 17, 2025. The analyst firm set a price target for $3.00 expecting NXTC to rise to within 12 months (a possible 476.92% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NextCure (NXTC)?
The latest analyst rating for NextCure (NASDAQ:NXTC) was provided by HC Wainwright & Co., and NextCure reiterated their buy rating.
When was the last upgrade for NextCure (NXTC)?
There is no last upgrade for NextCure
When was the last downgrade for NextCure (NXTC)?
The last downgrade for NextCure Inc happened on November 4, 2022 when Ladenburg Thalmann changed their price target from N/A to N/A for NextCure Inc.
When is the next analyst rating going to be posted or updated for NextCure (NXTC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NextCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NextCure was filed on March 17, 2025 so you should expect the next rating to be made available sometime around March 17, 2026.
Is the Analyst Rating NextCure (NXTC) correct?
While ratings are subjective and will change, the latest NextCure (NXTC) rating was a reiterated with a price target of $3.00 to $3.00. The current price NextCure (NXTC) is trading at is $0.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.